Skip to main content

Advertisement

SpringerLink
Log in

Venetoclax monotherapy for cutaneous blastic plasmacytoid dendritic cell neoplasm

  • Letter to the Editor
  • Published:
Annals of Hematology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Chaperot L, Bendriss N, Manches O, Gressin R, Maynadie M, Trimoreau F, Orfeuvre H, Corront B, Feuillard J, Sotto JJ, Bensa JC, Brière F, Plumas J, Jacob MC (2001) Identification of a leukemic counterpart of the plasmacytoid dendritic cells. Blood 97:3210–3217. https://doi.org/10.1182/blood.v97.10.3210

    Article  CAS  PubMed  Google Scholar 

  2. Herling M, Teitell MA, Shen RR, Medeiros LJ, Jones D (2003) TCL1 expression in plasmacytoid dendritic cells (DC2s) and the related CD4+ CD56+ blastic tumors of skin. Blood 101:5007–5009. https://doi.org/10.1182/blood-2002-10-3297

    Article  CAS  PubMed  Google Scholar 

  3. Julia F, Petrella T, Beylot-Barry M, Bagot M, Lipsker D, Machet L, Joly P, Dereure O, Wetterwald M, d'Incan M, Grange F, Cornillon J, Tertian G, Maubec E, Saiag P, Barete S, Templier I, Aubin F, Dalle S (2013) Blastic plasmacytoid dendritic cell neoplasm: clinical features in 90 patients. Br J Dermatol 169:579–586. https://doi.org/10.1111/bjd.12412

    Article  CAS  PubMed  Google Scholar 

  4. Feuillard J, Jacob M-C, Valensi F, Maynadié M, Gressin R, Chaperot L, Arnoulet C, Brignole-Baudouin F, Drénou B, Duchayne E, Falkenrodt A, Garand R, Homolle E, Husson B, Kuhlein E, le Calvez G, Sainty D, Sotto MF, Trimoreau F, Béné MC (2002) Clinical and biologic features of CD4(+)CD56(+) malignancies. Blood 99:1556–1563. https://doi.org/10.1182/blood.v99.5.1556

    Article  CAS  PubMed  Google Scholar 

  5. Pagano L, Valentini CG, Pulsoni A, Fisogni S, Carluccio P, Mannelli F, Lunghi M, Pica G, Onida F, Cattaneo C, Piccaluga PP, di Bona E, Todisco E, Musto P, Spadea A, D'Arco A, Pileri S, Leone G, Amadori S, Facchetti F, for GIMEMA-ALWP (Gruppo Italiano Malattie EMatologiche dell'Adulto, Acute Leukemia Working Party) (2013) Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: an Italian multicenter study. Haematologica 98:239–246. https://doi.org/10.3324/haematol.2012.072645

    Article  PubMed  PubMed Central  Google Scholar 

  6. Pemmaraju N, Lane AA, Sweet KL, Stein AS, Vasu S, Blum W, Rizzieri DA, Wang ES, Duvic M, Sloan JM, Spence S, Shemesh S, Brooks CL, Balser J, Bergstein I, Lancet JE, Kantarjian HM, Konopleva M (2019) Tagraxofusp in Blastic Plasmacytoid Dendritic-Cell Neoplasm. N Engl J Med 380:1628–1637. https://doi.org/10.1056/NEJMoa1815105

    Article  CAS  PubMed  Google Scholar 

  7. Montero J, Stephansky J, Cai T, Griffin GK, Cabal-Hierro L, Togami K, Hogdal LJ, Galinsky I, Morgan EA, Aster JC, Davids MS, LeBoeuf NR, Stone RM, Konopleva M, Pemmaraju N, Letai A, Lane AA (2017) Blastic Plasmacytoid Dendritic Cell Neoplasm Is Dependent on BCL2 and Sensitive to Venetoclax. Cancer Discov 7:156–164. https://doi.org/10.1158/2159-8290.CD-16-0999

    Article  CAS  PubMed  Google Scholar 

  8. Grushchak S, Joy C, Gray A, Opel D, Speiser J, Reserva J, Tung R, Smith SE (2017) Novel treatment of blastic plasmacytoid dendritic cell neoplasm. Medicine (Baltimore) 96:e9452. https://doi.org/10.1097/MD.0000000000009452

    Article  Google Scholar 

  9. DiNardo CD, Rausch CR, Benton C et al (2018) Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies. Am J Hematol 93:401–407. https://doi.org/10.1002/ajh.25000

    Article  CAS  PubMed  Google Scholar 

Download references

Funding

Not applicable.

Author information

Authors and Affiliations

  1. Division of Hematology, Department of Medicine, Stanford University School of Medicine/Stanford Cancer Institute, 875 Blake Wilbur Drive, Palo Alto, Stanford, CA, 94304, USA

    Matthew Schwede, Irena T. Tan, Danielle F. Atibalentja & Gabriel N. Mannis

  2. Department of Dermatology, Stanford University School of Medicine, Stanford, CA, USA

    Meghan M. Dickman & Kerri E. Rieger

  3. Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA

    Kerri E. Rieger

Authors
  1. Matthew Schwede
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Irena T. Tan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Danielle F. Atibalentja
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Meghan M. Dickman
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Kerri E. Rieger
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Gabriel N. Mannis
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

All authors contributed to the study conception and design. Material preparation, data collection, and analysis were performed by MS, ITT, DFA, MD, KER, and GM. The first draft of the manuscript was written by MS, and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Matthew Schwede.

Ethics declarations

GM receives research funding from Glycomimetics, Gilead, and Jazz Pharmacuticals, and has served as an advisor/consultant for Abbvie, Agios, BMS, and Genentech. KR has served as a consultant for Pfizer.

Consent to participate

The patient in this case provided verbal consent to receive the treatment described after a discussion of risks and benefits. Consent was recorded in the medical record.

Ethics approval

Because this is a retrospective case report of a single patient and thus not considered human subjects research, the Institutional Review Board of Stanford University waived ethics approval.

Consent for publication

The participant has consented to the submission of the case report to the journal.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Schwede, M., Tan, I.T., Atibalentja, D.F. et al. Venetoclax monotherapy for cutaneous blastic plasmacytoid dendritic cell neoplasm. Ann Hematol 99, 2973–2975 (2020). https://doi.org/10.1007/s00277-020-04276-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-020-04276-z

Search

Navigation